Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma

Completed

• Conditions: Angiogenesis; Glioblastoma

• Registration Number: NCT04974983
• Lead Sponsor: University Hospital Regensburg

Brief Summary

This retrospective non - interventional patient chart review will be utilizing real world clinical data from patients treated for rGBM at the University Regensburg Medical center either with or without bevacizumab. Only patients will be analyzed who were potentially eligible for bevacizumab treatment. The study is designed to investigate the potential effects of bevacizumab treatment on the functional status, symptom burden, neurological deficits, time to tumor progression and overall survival between cohorts potentially eligible for bevacizumab.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-09-01
• Primary Completion: 2020-06-30
• Study Completion: 2020-08-30
• Status Verified: 2021-07
• Study First Submitted: 2021-07-16
• Study First Submitted QC: 2021-07-16
• Last Update Submitted: 2021-07-16
• Study First Posted: 2021-07-23
• Last Update Posted: 2021-07-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Not specified
• Target Recruitment: 203

Inclusion Criteria

Diagnosis of recurrent glioblastoma

Exclusion Criteria

Severe neurocognitive deficits

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Functional outcome	15 months	Neurological deficits impacting functional independency

Trial Locations

Locations (1)

University Hospital Regensburg; 🇩🇪 Regensburg, Germany